ES3011982T3 - Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof - Google Patents
Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof Download PDFInfo
- Publication number
- ES3011982T3 ES3011982T3 ES19875615T ES19875615T ES3011982T3 ES 3011982 T3 ES3011982 T3 ES 3011982T3 ES 19875615 T ES19875615 T ES 19875615T ES 19875615 T ES19875615 T ES 19875615T ES 3011982 T3 ES3011982 T3 ES 3011982T3
- Authority
- ES
- Spain
- Prior art keywords
- glp1
- gdf15
- peptide
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748603P | 2018-10-22 | 2018-10-22 | |
| PCT/IB2019/059029 WO2020084496A1 (en) | 2018-10-22 | 2019-10-22 | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3011982T3 true ES3011982T3 (en) | 2025-04-08 |
Family
ID=70330680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19875615T Active ES3011982T3 (en) | 2018-10-22 | 2019-10-22 | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11713345B2 (de) |
| EP (2) | EP3870211B1 (de) |
| JP (2) | JP7539902B2 (de) |
| KR (1) | KR20210081389A (de) |
| CN (2) | CN119751697A (de) |
| AU (2) | AU2019368816B2 (de) |
| BR (1) | BR112021007376A2 (de) |
| CA (1) | CA3116983A1 (de) |
| CL (1) | CL2021000987A1 (de) |
| CO (1) | CO2021005051A2 (de) |
| CR (1) | CR20210193A (de) |
| DO (1) | DOP2021000075A (de) |
| EA (1) | EA202191105A1 (de) |
| EC (1) | ECSP21028914A (de) |
| ES (1) | ES3011982T3 (de) |
| IL (1) | IL282297B1 (de) |
| JO (1) | JOP20210084A1 (de) |
| MX (1) | MX2021004665A (de) |
| MY (1) | MY205905A (de) |
| PE (1) | PE20211078A1 (de) |
| PH (1) | PH12021550885A1 (de) |
| SA (1) | SA521421825B1 (de) |
| SG (1) | SG11202103990QA (de) |
| WO (1) | WO2020084496A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| EP3870211B1 (de) | 2018-10-22 | 2025-01-08 | Janssen Sciences Ireland Unlimited Company | Glucagon-like peptid 1 (glp1)-wachstumsdifferenzierungsfaktor 15 (gdf15)-fusionsproteine und deren verwendungen |
| EP3883960A4 (de) * | 2018-11-20 | 2022-11-09 | Janssen Pharmaceutica NV | Gdf15-analoga und verfahren zur verwendung zur verringerung des körpergewichts und/oder zur reduzierung der nahrungsaufnahme |
| EP3934679A1 (de) * | 2019-03-08 | 2022-01-12 | Amgen Inc. | Kombinationstherapie mit wachstumsdifferenzierungsfaktor 15 |
| CN115260313B (zh) * | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| US11981718B2 (en) * | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022221291A2 (en) * | 2021-04-12 | 2022-10-20 | University Of Florida Research Foundation Incorporated | Compositions and methods for treating obesity |
| CA3219645A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
| AU2022278933A1 (en) * | 2021-05-21 | 2023-12-07 | Yuhan Corporation | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| AU2023381360A1 (en) * | 2022-11-18 | 2025-05-22 | Yuhan Corporation | Dual function proteins and uses thereof |
| CN116813742A (zh) * | 2022-11-22 | 2023-09-29 | 杭州博茵生物技术有限公司 | 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用 |
| WO2024144431A1 (ru) * | 2022-12-29 | 2024-07-04 | Авва Фармасьютикалс Лтд | Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1 |
| CN120897999A (zh) * | 2023-01-20 | 2025-11-04 | 韩国科学技术院 | 靶向gfral的反义寡聚物及其用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| BR0116024A (pt) * | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| US20090099031A1 (en) | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
| AU2007275294A1 (en) * | 2006-07-18 | 2008-01-24 | Centocor, Inc. | Human GLP-1 mimetibodies, compositions, methods and uses |
| PE20091931A1 (es) * | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| JP5444363B2 (ja) | 2008-10-31 | 2014-03-19 | セントビンセンツ ホスピタル シドニー リミテッド | 慢性腎疾患における予後判定の方法 |
| AR075240A1 (es) | 2009-02-06 | 2011-03-16 | Syngenta Participations Ag | Modificacion de enzima multidominio para la expresion en plantas |
| TW201101990A (en) | 2009-07-08 | 2011-01-16 | zhen-zheng Huang | Plant media |
| US20110015130A1 (en) | 2009-07-20 | 2011-01-20 | Woei-Jer Chuang | Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
| WO2012091564A2 (en) | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
| CN104039830A (zh) | 2011-11-04 | 2014-09-10 | 诺华股份有限公司 | 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体 |
| JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子１５（ｇｄｆ−１５）ポリペプチド |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| RS57422B1 (sr) | 2013-01-25 | 2018-09-28 | Janssen Biotech Inc | Antagonisti kv1.3 i postupci za upotrebu |
| CA2899170C (en) | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| KR20160021183A (ko) * | 2013-06-20 | 2016-02-24 | 노보 노르디스크 에이/에스 | Glp-1 유도체 및 그것의 용도 |
| TWI648401B (zh) | 2013-07-31 | 2019-01-21 | 安美基公司 | 生長分化因子１５（ｇｄｆ－１５）構築體 |
| GB201403794D0 (en) * | 2014-03-04 | 2014-04-16 | Univ Manchester | Novel antimicrobial peptides |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3157947A1 (de) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15-fusionspolypeptid und verwendung davon |
| EP3160496B1 (de) | 2014-06-24 | 2021-03-03 | Novo Nordisk As | Mic-1-fusionsproteine und verwendungen davon |
| MX370115B (es) | 2014-07-30 | 2019-12-02 | Ngm Biopharmaceuticals Inc | Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos. |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| PL3212226T3 (pl) | 2014-10-31 | 2020-11-02 | Ngm Biopharmaceuticals, Inc. | Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych |
| GB201512733D0 (en) | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| CN108367053A (zh) | 2015-12-22 | 2018-08-03 | 诺华股份有限公司 | 使用生长分化因子15(gdf-15)治疗或改善代谢性疾病的方法 |
| CN108697795A (zh) | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral受体疗法 |
| US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| CN109414471A (zh) | 2016-05-24 | 2019-03-01 | 诺和诺德股份有限公司 | Mic-1化合物及其用途 |
| EP3526346A1 (de) | 2016-10-12 | 2019-08-21 | Janssen Biotech, Inc. | Verfahren zum screening auf modulatoren der gdf15-artigen biologischen aktivität |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| EP3870211B1 (de) | 2018-10-22 | 2025-01-08 | Janssen Sciences Ireland Unlimited Company | Glucagon-like peptid 1 (glp1)-wachstumsdifferenzierungsfaktor 15 (gdf15)-fusionsproteine und deren verwendungen |
| EP3883960A4 (de) | 2018-11-20 | 2022-11-09 | Janssen Pharmaceutica NV | Gdf15-analoga und verfahren zur verwendung zur verringerung des körpergewichts und/oder zur reduzierung der nahrungsaufnahme |
-
2019
- 2019-10-22 EP EP19875615.7A patent/EP3870211B1/de active Active
- 2019-10-22 JP JP2021546056A patent/JP7539902B2/ja active Active
- 2019-10-22 WO PCT/IB2019/059029 patent/WO2020084496A1/en not_active Ceased
- 2019-10-22 US US17/309,114 patent/US11713345B2/en active Active
- 2019-10-22 CN CN202411964603.3A patent/CN119751697A/zh active Pending
- 2019-10-22 AU AU2019368816A patent/AU2019368816B2/en active Active
- 2019-10-22 SG SG11202103990QA patent/SG11202103990QA/en unknown
- 2019-10-22 MX MX2021004665A patent/MX2021004665A/es unknown
- 2019-10-22 CN CN201980085401.2A patent/CN113226351B/zh active Active
- 2019-10-22 EP EP25150545.9A patent/EP4520343A3/de active Pending
- 2019-10-22 MY MYPI2021002147A patent/MY205905A/en unknown
- 2019-10-22 CR CR20210193A patent/CR20210193A/es unknown
- 2019-10-22 IL IL282297A patent/IL282297B1/en unknown
- 2019-10-22 KR KR1020217015121A patent/KR20210081389A/ko active Pending
- 2019-10-22 PE PE2021000543A patent/PE20211078A1/es unknown
- 2019-10-22 BR BR112021007376-0A patent/BR112021007376A2/pt unknown
- 2019-10-22 CA CA3116983A patent/CA3116983A1/en active Pending
- 2019-10-22 ES ES19875615T patent/ES3011982T3/es active Active
- 2019-10-22 EA EA202191105A patent/EA202191105A1/ru unknown
-
2021
- 2021-04-19 CL CL2021000987A patent/CL2021000987A1/es unknown
- 2021-04-20 CO CONC2021/0005051A patent/CO2021005051A2/es unknown
- 2021-04-21 DO DO2021000075A patent/DOP2021000075A/es unknown
- 2021-04-21 PH PH12021550885A patent/PH12021550885A1/en unknown
- 2021-04-22 JO JOP/2021/0084A patent/JOP20210084A1/ar unknown
- 2021-04-22 EC ECSENADI202128914A patent/ECSP21028914A/es unknown
- 2021-04-22 SA SA521421825A patent/SA521421825B1/ar unknown
-
2023
- 2023-06-09 US US18/332,690 patent/US12275770B2/en active Active
-
2024
- 2024-08-14 JP JP2024135217A patent/JP2024170428A/ja active Pending
-
2025
- 2025-03-06 US US19/072,966 patent/US20250197468A1/en active Pending
- 2025-04-30 AU AU2025203071A patent/AU2025203071A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3011982T3 (en) | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof | |
| KR102865076B1 (ko) | 글루카곤-유사 펩티드 1(glp-1) 융합 펩티드 커플링된 사이클릭 펩티드 티로신 티로신 접합체 및 이의 용도 | |
| US11780900B2 (en) | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | |
| HK40120308A (zh) | 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途 | |
| EA050724B1 (ru) | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение | |
| HK40060006A (en) | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof | |
| HK40060006B (zh) | 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途 | |
| CN120230224A (zh) | 一种glp1/gdf15双重激动剂 | |
| HK40045710A (en) | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | |
| HK40045710B (en) | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |